Tragic Case Highlights Need for Earlier Cholangiocarcinoma Diagnosis

A mother of three who tragically died days after receiving a liver cancer diagnosis highlights the alarming inefficacy in healthcare systems worldwide. Sian Ashcroft, aged 35, succumbed to cholangiocarcinoma (CCA), a type of bile duct cancer, 18 days after diagnosis. Her story is a stark reminder of the urgent need for better early detection and treatment options.

CCA has a dismal five-year survival rate of 2-9%, remarkably lower compared to the overall cancer survival rate in England, which stands at 54%, according to the Cholangiocarcinoma Awareness and Medical Fund (AMMF). This stark disparity underscores the critical need for increased awareness and research into this understudied cancer.

AMMF’s research indicates that patients are frequently diagnosed at advanced stages, with more than 50% receiving no cancer-specific treatment. These shocking statistics highlight the profound shortcomings in the current diagnostic and treatment protocols surrounding CCA.

The Royal College of General Practitioners acknowledges the challenges in diagnosing certain cancers in primary care settings. Time constraints and a high workload often限制 GPs from thoroughly investigating symptoms that might indicate less common conditions like bile duct cancer.

Despite these hurdles, the proportion of cancers diagnosed after GP referrals has increased. In 2020, 60% of cancers were diagnosed following referral, underscoring the critical role GPs play in the initial stages of patient care.

Sian Ashcroft’s story begins with the discovery of anaemia during a blood donation attempt in the spring of 2023. After taking iron supplements, she continued to experience abdominal pain, initially attributing it to food poisoning. However, the pain persisted, leading to a GP referral and eventually hospital admission.

Initial tests suggested gallstones, but the pain worsened, necessitating surgery to insert a stent in her bile duct. In January 2024, the diagnosis revealed terminal cholangiocarcinoma, leaving her with a prognosis of months rather than years. She passed away 18 days later.

Her mother, Sue Dowling, describes Sian’s prognosis as an “incredible shock.” Despite frequent GP visits and hospital stays, the diagnosis came too late. Sian’s positive outlook, bravery, and unwavering focus on her family left a lasting impression on those close to her.

Helen Morement, CEO of AMMF, shares the grim reality: most CCA diagnoses occur at late stages, with only about 21% being identified early. Unlike other liver cancers, CCA does not uniformly correlate with traditional risks such as cirrhosis, viral hepatitis, alcohol abuse, or lifestyle factors.

Morement emphasizes the need for a paradigm shift in how CCA is perceived and treated. New data indicates a significant rise in CCA cases in England, nearly on par with the more common hepatocellular carcinoma. Given CCA’s poor prognosis, this trend is alarming.

The charity’s research shows that more than half of CCA patients do not receive cancer-specific treatments. This lack of awareness about treatment options is a critical barrier to improving patient outcomes.

On World Cholangiocarcinoma Day, AMMF’s “Rethink Liver Cancer” campaign aims to raise awareness and advocate for better diagnostic practices and treatment options. The Royal Liver Building in Liverpool is set to turn purple as part of these efforts, commemorating Sian Ashcroft’s life and fighting against this devastating disease.

Morement urges clinicians, health planners, and policymakers to reconsider their approach to CCA. Implementing routine liver function tests for patients presenting with vague symptoms could lead to earlier diagnoses and better management of the disease.

The Royal College of General Practitioners understands the pressures of the job but stresses the importance of thorough symptom investigations, even when initial indicators seem benign.

As we reflect on Sian Ashcroft’s life and the impact of cholangiocarcinoma, the call to action is clear. We must prioritize early diagnosis, raise awareness about this lethal form of cancer, and support the patients and families affected by it.

To learn more about AMMF’s mission and to support their efforts, visit their website or get involved with local awareness campaigns. Together, we can make a difference.

Share your thoughts and stories in the comments below or join our mailing list to stay updated on the latest developments in the fight against cholangiocarcinoma. Your support is invaluable.